| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | 1 | — | — | — | — |
| Sell | — | — | 1 | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2018 | ‡‡‡ |
|
| 2017 | ‡‡‡ |
|
| 2016 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 4.31 | 4.60 | 8.83 | 10.90 |
| Receivables | 42.31 | 46.86 | 39.95 | 39.74 |
| Inventory | 131.31 | 126.35 | 120.72 | 119.96 |
| Other | 4.92 | — | — | — |
| 182.85 | 181.94 | 173.06 | 174.42 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 27.19 | 31.00 | 27.37 | 25.32 |
| ST’ Debt | 23.08 | 43.82 | 36.28 | 57.27 |
| Other | 31.83 | — | — | — |
| 97.82 | 129.66 | 110.96 | 128.91 |
| 10y | 5y | 3y | |
| Sales | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Book Value | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Dec | Mar | Jun | Sep | Year | |
|---|---|---|---|---|---|
| ’26 | 108.54 | 102.90 | 108.91 | — |
—
|
| ’25 | 111.51 | 107.01 | 112.53 | 113.89 |
444.94
|
| ’24 | 117.59 | 118.63 | 123.88 | 112.74 |
472.84
|
| ’23 | 68.99 | 91.12 | 91.52 | 103.55 |
355.17
|
| ’22 | 75.16 | 69.71 | 68.27 | 73.78 |
286.91
|
| ’21 | 62.45 | 70.89 | 69.10 | 70.54 |
272.98
|
| ’20 | 42.00 | 46.43 | 42.47 | 60.82 |
191.72
|
| Dec | Mar | Jun | Sep | Year | |
|---|---|---|---|---|---|
| ’26 | 9.85 | (2.79) | 7.60 | — |
—
|
| ’25 | 9.40 | 0.23 | 12.28 | 6.76 |
28.67
|
| ’24 | 7.87 | (5.74) | 11.75 | 6.73 |
20.61
|
| ’23 | 6.25 | 7.92 | 11.83 | (0.01) |
26.00
|
| ’22 | 4.24 | 1.01 | 5.59 | (4.44) |
6.40
|
| ’21 | 7.67 | 13.24 | 11.29 | (3.01) |
29.19
|
| ’20 | 3.00 | 3.57 | 11.50 | 10.72 |
28.79
|
| Dec | Mar | Jun | Sep | Year | |
|---|---|---|---|---|---|
| ’26 | 8.51 | (4.71) | 5.31 | — |
—
|
| ’25 | 7.58 | (2.27) | 10.84 | 4.82 |
20.98
|
| ’24 | 6.22 | (7.46) | 10.13 | 3.26 |
12.14
|
| ’23 | 4.97 | 6.31 | 11.23 | (6.43) |
16.08
|
| ’22 | 1.17 | (3.43) | 4.79 | (8.25) |
(5.71)
|
| ’21 | 4.41 | 11.03 | 8.29 | (5.96) |
17.77
|
| ’20 | 2.35 | 2.36 | 10.98 | 9.22 |
24.91
|
| Dec | Mar | Jun | Sep | Year | |
|---|---|---|---|---|---|
| ’26 | (0.02) | (0.80) | (0.34) | — |
—
|
| ’25 | 0.16 | 5.05 | 1.24 | (0.04) |
4.93
|
| ’24 | (0.22) | (1.04) | (0.91) | (6.32) |
(8.48)
|
| ’23 | 0.60 | 0.49 | 0.33 | (1.46) |
(0.03)
|
| ’22 | 2.04 | 4.84 | 1.11 | (0.20) |
7.84
|
| ’21 | 3.45 | 5.62 | 3.01 | 2.49 |
9.80
|
| ’20 | 0.15 | 0.66 | 1.07 | 1.22 |
6.40
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 22.81 | 22.61 | 8.69 | 6.25 | — | — | — |
Low Price
|
| ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | 45.00 | 40.38 | 28.45 | 25.88 | — | — | — |
High Price
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1,249 | 1,751 | 1,770 | 1,744 | — | — | — |
Employees
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.23 | 0.20 | 0.27 | 0.26 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 286.91 | 355.17 | 472.84 | 444.94 | ‡‡‡‡‡ | — | — |
Revenue
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 34.10% | 32.54% | 30.63% | 32.74% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 31.62 | 1.47 | (31.34) | 28.40 | — | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 11.02% | 0.41% | (6.63%) | 6.38% | ‡‡‡ | — | — |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 24.74 | (0.10) | (26.68) | 22.74 | ‡‡‡‡‡ | — | — |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 8.14 | 19.14 | 24.15 | 21.89 | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 92.08 | 113.33 | 150.20 | 143.81 | ‡‡‡‡‡ | — | — |
Revenue/Sh
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | 7.94 | (0.03) | (8.48) | 7.35 | ‡‡‡‡ | — | — |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.05 | 8.29 | 6.55 | 9.27 | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (3.89) | (3.16) | (2.69) | (2.49) | ‡‡‡ | — | — |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.83) | 5.13 | 3.86 | 6.78 | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 31.18 | 31.95 | 23.15 | 30.80 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.12 | 3.13 | 3.15 | 3.09 | ‡‡‡‡‡ | — | — |
Shares
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.52 | 0.00 | 0.00 | 2.50 | ‡‡‡‡ | — | — |
PE Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.27 | 0.25 | 0.10 | 0.13 | ‡‡‡ | — | — |
PS Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.80 | 0.88 | 0.66 | 0.60 | ‡‡‡ | — | — |
PB Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.62 | 0.74 | 0.48 | 0.46 | ‡‡‡‡ | — | — |
EV/Sales
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (28.05) | 17.08 | 19.85 | 10.05 | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6.40 | 26.00 | 20.61 | 28.67 | ‡‡‡ | — | — |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (12.11) | (9.91) | (8.47) | (7.69) | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (5.71) | 16.08 | 12.14 | 20.98 | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 78.42 | 85.03 | 52.28 | 62.10 | — | — | — |
Working Cap'
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 103.21 | 180.64 | 185.78 | 156.94 | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 98.61 | 176.33 | 181.18 | 148.11 | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 97.16 | 100.14 | 72.89 | 95.30 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 10.09% | (0.03%) | (6.44%) | 5.73% | — | — | — |
ROA
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 8.28% | 3.49% | (3.36%) | 3.76% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 28.73% | (0.10%) | (30.84%) | 27.04% | — | — | — |
ROE
|
Live Ventures Incorporated (LIVE), a micro-cap conglomerate spanning e-commerce, medical billing, and niche goods, boasts explosive revenue growth from $79 million in 2016 to a 2024 peak of $473 million—a 500% surge driven by aggressive acquisitions. Yet, this scale masks deepening cracks: profitability has swung wildly from peaks like $31 million net income in 2021 to a $27 million loss in 2024, with gross margins eroding from 41% to 31%, revenue per share halving amid dilution, and free cash flow turning erratic. The stock, trading at depressed levels implying 600% upside to analyst targets, tantalizes value hunters but raises red flags as a potential trap amid decelerating sales (projected 11% drop by 2026) and execution risks.
Balance sheet strains amplify the caution: debt ballooned 964% to $186 million by 2024, pushing net debt-to-equity over 100% in a high-rate environment, while ROIC plunged to -3% from 17%. Insider optimism shines through, however, with the CEO snapping up nearly 93,000 shares at ~$7.70 in 2025—dwarfing minor sells—signaling confidence at 40% below recent highs. Cheap multiples (PS 0.13x, PE 2.5x forward) scream bargain, but historical decoupling of stock from fundamentals post-2021 questions sustainability.
Analysts forecast a rebound—2025 net income to $23 million and FCF $21 million—but contrarians eye macro headwinds, margin fragility, and acquisition indigestion as derailers. Is LIVE a speculative recovery gem backed by insiders, or a leveraged bet on unproven turnaround magic? The full analysis unpacks the metrics and risks.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.